Tue, Oct 21, 2014, 10:50 AM EDT - U.S. Markets close in 5 hrs 10 mins


% | $
Quotes you view appear here for quick access.

Rite Aid Corporation Message Board

busy26795 68 posts  |  Last Activity: Oct 20, 2014 10:15 AM Member since: Aug 26, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • GLDD Great Lakes Dredge & Dock announces contract signing ceremony in Cairo to Deepen and Widen the Suez Canal; contract is valued at $540 million and is part of a larger project to expand global trade and strengthen the economy in Egypt

    Co announced that the Chairman of the Suez Canal Authority, Mohab Mohamed Hussein Mamish, in the presence of the Prime Minister of Egypt, Ibrahim Mahlab, signed a contract with the Consortium consisting of Great Lakes (25%) and Dredging International NV (75%) for Lot 6 of the widening and deepening of the Suez Canal. The contract is valued at $540 mln and is part of a larger project to expand global trade and strengthen the economy in Egypt.

    Sentiment: Strong Buy

  • 16-Oct-14 07:58 ET


    HCA target raised to $83 at RBC Capital Mkts (64.84)
    RBC Capital Mkts raises their HCA tgt to $83 from $80. They expect strength in hospital stocks after HCA prereleased 3Q14 upside and raised guidance—and stronger than the market had hoped for. They wonder if a buyback of PE shares could be next and are increasing their FY14 and FY15 estimates.

    15-Oct-14 16:54 ET
    HCA sees Q3 revs of ~$9.22 bln vs $9.04 bln Capital IQ Consensus Estimate; raises FY14 adjusted EPS and adjusted EBITDA guidance

    Co announced preliminary financial and operating results for the third quarter ended September 30, 2014.

    Co sees Q3 revs of ~$9.22 bln vs $9.04 bln Capital IQ Consensus Estimate; sees EPS of $1.16 vs $0.96 Capital IQ Consensus Estimate; sees adjusted EBITDA of ~$1.828 bln

    "During the quarter ended September 30, 2014, HCA recorded two changes in estimates which had the net effect of increasing revenues approximately $26 million."

    Same facility admissions for the third quarter of 2014 increased 2.8 percent while same facility equivalent admissions increased 4.1 percent. Same facility uninsured admissions and equivalent admissions for the third quarter of 2014 declined 14.8 percent and 8.9 percent, respectively. Same facility emergency room visits increased 7.3 percent from the prior year's third quarter.

    Same facility revenue per equivalent admission, excluding Texas Medicaid Waiver and RAC adjustments, is expected to increase approximately 3.5 percent in the third quarter of 2014 compared to the prior year's third quarter.

    Co sees FY14 revs of $36.5-37.0 bln (raised from $36.0-36.5 bln) vs $36.45 bln Capital IQ Consensus Estimate; sees adjusted EPS of $4.40-4.60 (raised from $4.00-4.25) vs $4.21 Capital IQ Consensus Estimate; sees adjusted EBITDA of $7.25-7.35 bln (raised from $7.00-7.15 bln); CapEx guidance unchanged at ~$2.2 bln

    Sentiment: Strong Buy

  • SUNE SunEdison signs joint venture agreement with JIC Capital to penetrate the chinese solar market (15.11)

    Sentiment: Strong Buy

  • TK Teekay Shipping target raised premarket to $100 at Deutsche Bank; Buy

    Deutsche Bank raises their TK tgt to $100 from $90. TK offers an extremely compelling investment opportunity given its LT and locked in fee-based rev stream, and well capitalized daughter co's allowing for the vast majority of its growing cash flow to be returned to shareholders. As a result, DB sees significant upside in TK shares as co's highly capable mgmt team executes on its vision of shifting co from a cyclical to secular cash flow story. Ultimately firm see's potential for TK's dividend to increase by more than 3x by 2018 (vs. 2014), which should easily translate to a triple-digit stock on an npv basis.

    Sentiment: Strong Buy

  • TK Upgrades in the month of October

    Teekay price target raised to $75-$90 from $64-$76 at Wells Fargo Wells Fargo increased its price target on Teekay after attending the company's Investor Day, as the firm thinks the company has formally positioned itself as a multi-year, high-growth GP story. The firm notes that the company provided 2015 dividend guidance that implies a $1 per share, year-over-year increase, and says that the company is now well-positioned among its peers as far as its dividend is concerned. The firm keeps an Outperform rating on the shares

    Teekay price target raised to $100 from $90 at Deutsche Bank
    Deutsche Bank raised its price target for Teekay shares to $100 saying the company's cash flow growth is moving from cyclical to secular. The firm views the stock as an "extremely compelling investment opportunity" and keeps a Buy rating on the name

    Teekay price target raised to $90 from $80 at RBC Capital
    RBC Capital increased its price target on Teekay after the company announced a higher than expected dividend. The firm keeps an Outperform rating on the shares

    Teekay upgraded to Buy from Hold at Deutsche Bank
    Deutsche Bank upgraded Teekay to Buy citing the company's plans to raise its dividend by 80%. Deutsche raised its price target for shares to $90 from $68 saying the plan is better than it expected

    Sentiment: Strong Buy

  • News Breaks

    October 15, 2014


    PowerSecure data center energy services acquisition positive, says RW Baird Baird said PowerSecure's acquisition of Power Design's data center energy services business is a positive as it expands the company's offerings and pipeline and should help PowerSecure further penetrate the data center market. Baird Outperform rating and $17 price target on PowerSecure shares

    PowerSecure acquisition positive, says Roth Capital
    After PowerSecure (POWR) announced it acquired the data center energy services business of Power Design, Roth Capital says the deal should accelerate PowerSecure's penetration into the data center market at what appears to be an attractive price. The firm reiterates a $14 price target and Buy rating on the shares.

    PowerSecure adds $25M in new business PowerSecure has been awarded approximately $14M of new distributed generation business, approximately $9M of new utility infrastructure business and approximately $2M of new energy efficiency business. The $25M in new business is expected to be recognized fairly evenly from 4Q14 through 2015. PowerSecure CEO stated that the company has "added approximately $215M in new business to our backlog over the past three months across all three of our business segments."

    Sentiment: Strong Buy

  • busy26795 busy26795 Oct 13, 2014 2:07 PM Flag

    yes the Canadian gov't developed this..... Tom Geisbert now at UT ..is co-developer. Canada kept the intellectual property.

    NLNK will profit -- the gov't will pay them to get it out there and the gov't is paying for the trial --- according to Geisbert ...this is a darn good vaccine

    Sentiment: Strong Buy

  • Ebola stocks: 2 to sell, and 5 to consider buying
    By Nigam Arora

    Published: Oct 13, 2014 12:08 p.m. ET
    Stocks to Buy

    All small Ebola-related stocks are highly speculative and carry extremely high risk of loss. Most promising are companies that are working on vaccines. If a vaccine is successfully developed, it may quickly become a sustainable big business. Two companies of note are NewLink Genetics NLNK, +1.49% and Inovio Pharmaceuticals INO, +2.38%

    Sentiment: Strong Buy

  • Canadian Ebola vaccine safety trials move ahead, NewLink Genetics says
    Vaccine vials donated by Canada all in pool for use in clinical studies

    By Helen Branswell, The Canadian Press Posted: Oct 08, 2014 2:36 PM ET Last Updated: Oct 08, 2014 2:36 PM ET

    Sentiment: Strong Buy

  • EXXI Kyle Bass buys the dip in Energy XXI • 4:12 PM

    Stephen Alpher, SA News Editor

    Hayman Capital files a 13G disclosing a passive 5.08% stake in Energy XXI (EXXI -6.6%).

    The stock is lower by 62% YTD.

    Sentiment: Strong Buy

  • busy26795 busy26795 Oct 2, 2014 2:00 PM Flag

    Me too...thinking the real deal

    Sentiment: Strong Buy

  • TMUS

    Shorts have been chopping this down but they will have to respect the M&A chatter which I think will drive them to cover here.

    Sentiment: Strong Buy

  • TMUS

    T-Mobile US follow-up; Bloomberg reporting Iliad (ILIAY) planning to bid for stake with offer of ~ $33/share

    Sentiment: Strong Buy

  • NLNK NewLink Genetics new CFO positive, says Cantor

    After NewLink appointed a new CFO, Cantor views his commercial background as positive. The firm believes that the company made the move because it wanted a CFO with greater commercial experience. The firm keeps a $34 price target and Buy rating on the shares.

  • Reply to

    Your new CFO

    by minnesotafarmcountry Oct 1, 2014 6:23 PM
    busy26795 busy26795 Oct 2, 2014 6:51 AM Flag

    They are lucky to get him!


    Sentiment: Strong Buy

  • $NLNK Newlink Genetics +7%- developing an Ebola vaccine. CEO joins us in a CNBCFastMoney EXCLUSIVE 5p


  • Tekmira Pharma moves back toward highs; latest move follows CNBC segment with Pura Vida healthcare analyst who said TKMR has the ability to produce the drug in scale

    Dr. Neil Shahrestani of Pura Vida discussed TKMR, noting mgmt indicated they have the ability to produce the drug in scale, and he noted SRPT is a name that is in the consortium trials... Notes NLNK and GSK are the frontrunners on the vaccine side.,

    NLNK NewLink Genetics: CNBC's Melissa Lee says NLNK CEO (Ebola play) will be on Fast Money tonight.

    Shs Float 19.88M Short Float 29.28%

    Sentiment: Strong Buy

  • busy26795 by busy26795 Sep 29, 2014 11:51 AM Flag

    MKTO on MM tonight

    Sentiment: Strong Buy

  • AbbVie's HUMIRA receives U.S. FDA approval for the treatment of pediatric patients with moderately to severely active Crohn's Disease

    Co announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA (adalimumab) for reducing signs and symptoms, and achieving and maintaining clinical remission, in pediatric Crohn's disease patients 6 years of age and older when certain other treatments have not worked well enough. This FDA approval represents the eighth indication for HUMIRA in the United States and makes it the first and only biologic treatment approved for use in this patient population that can be administered at home.

    Sentiment: Strong Buy

  • busy26795 busy26795 Sep 24, 2014 12:06 PM Flag

    CVTS is a development stage biopharmaceutical company focused on treatments for Parkinson's Disease. Its lead product candidate, CVT-301, is in the later stages of development, however, with Phase 3 trials expected early in 2015. Further, Civitas believes that CVT-301 will qualify for review through the 505(b)(2) pathway, allowing for an abbreviated pathway to approval in the US. CVT-301, which it purchased from Alkermes in 2010, is comprised of proprietary formulated dry powder capsules containing L-dopa, which are administered through a proprietary, easy to use, reusable inhaler. CVT-301 is being developed as a self-administered, as-needed, inhaled L-dopa therapy for OFF episodes, providing rapid delivery of L-dopa to the brain to be used in conjunction with a patient's individually optimized oral L-dopa regimen.

    The potential market size is considerable with approximately one million people in the U.S. and between seven to ten million worldwide diagnosed with PD. Symptoms include tremors at rest, rigidity and impaired movement.

4.85+0.09(+1.89%)10:49 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.